Success Metrics

Clinical Success Rate

14.3%

Based on 1 completed trials

Completion Rate

14%(1/7)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

6(86%)

Phase Distribution

Ph phase_3

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

3(42.9%)

Phase 3Large-scale testing

4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

14.3%

1 of 7 finished

Non-Completion Rate

85.7%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(6)

Detailed Status

Terminated6

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

14.3%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (42.9%)

Phase 34 (57.1%)

Trials by Status

completed114%

terminated686%

Recent Activity

0 active trials

Showing 5 of 7

terminatedphase_3

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197145

terminatedphase_2

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778

terminatedphase_2

GW873140 In Combination With Combivir In HIV Infected Subjects

NCT00104429

terminatedphase_3

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890

terminatedphase_3

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197197

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00197145Phase 3

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Terminated

NCT00102778Phase 2

GW873140 In Combination With Kaletra In HIV Infected Subjects

Terminated

NCT00104429Phase 2

GW873140 In Combination With Combivir In HIV Infected Subjects

Terminated

NCT00123890Phase 3

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

Terminated

NCT00197197Phase 3

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

Terminated

NCT00297076Phase 3

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Terminated

NCT00076284Phase 2

GW873140 to Treat HIV-1 Infected Adults

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7